Added to YB: 2026-05-11
Pitch date: 2026-05-06
QURE [bullish]
uniQure N.V.
+19.48%
current return
Author Info
No bio for this author
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$2.9B
Pitch Price
$22.59
Price Target
N/A
Dividend
N/A
EV/EBITDA
-17.10
P/E
-13.28
EV/Sales
159.09
Sector
Biotechnology
Category
value
uniQure (QURE): Cash-Rich, Pipeline-Heavy, and Deeply Mispriced
QURE: Clinical-stage gene therapy at negative EV w/ $586.6M cash (runway to H2 2029). AMT-260 (epilepsy) Q2 2026 data readout catalyst. AMT-130 (HD) showed 75% slowing of progression at 36mo, UK MAA filing Q3 2026. FDA Type B meeting Q2 to negotiate new trial designs after initial rejection. Trading sub-$30 ignores clinical validation & balance sheet strength.
Read full article (3 min)